

## Epogen - (40,000 Unit/mL; Vial, Multidose)

<b>Generic Name</b>	Epoetin alfa	<b>Innovator</b>	Amgen
<b>Dosage</b>	40,000 Unit/mL; Vial, Multidose	<b>Branded US Sales</b>	More Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	Less Than 5	<b>Generic Launches</b>	Less Than 5
<b>Indication</b>	Epogen is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.